Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the diagnostic potential of choline measurements by in vivo magnetic resonance spectroscopy (MR spectroscopy) for diagnosis of renal masses.

Methods

Twenty-eight patients with 29 renal lesions underwent prospectively preoperative 3 T MR spectroscopy of renal masses before diagnostic tissue confirmation. A respiratory-triggered single-voxel MR spectroscopy was performed in these masses using the point-resolved spectroscopy (TR, 2,000 ms, TE, 135 ms) sequence. The spectra were analyzed for choline resonances at 3.23 ppm, which were normalized by the noise outside the diagnostic range of the spectra. Image and spectra analyses were conducted blinded to all patient-related data. Histological results of the surgical resection or image-guided biopsy specimen were defined as the standard of reference. Appropriate statistical tests were used.

Results

Seventeen lesions were histopathologically malignant, and 12 lesions were benign. Mean choline SNR in malignant lesions was 2.9 and 1.33 in benign lesions (P = 0.019). ROC analysis revealed an area under the curve of 0.721 and SE 0.0763 with a P value of 0.0038. A Cho SNR ≥2 as cutoff for malignancy resulted in a sensitivity and specificity of 52.9 % (95 % CI 27.8–77.0 %) and 91.7 % (61.5–99.8 %), respectively. Although not significant, choline was observed more regularly in G3 (4 out of 5) compared with G2 (5 out of 12) RCC (P > 0.05).

Conclusions

We could demonstrate the potential role of in vivo MR spectroscopy as a tool for differentiating benign from malignant masses with a high positive predictive value of 90 %. Furthermore, choline may be a biomarker of RCC aggressiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98:1331–1334

    Article  PubMed  Google Scholar 

  2. Brookman-May S, Langenhuijsen JF, Volpe A et al (2013) Management of localized and locally advanced renal tumors. A contemporary review of current treatment options. Minerva Med 104:237–259

    CAS  PubMed  Google Scholar 

  3. Kovacs G, Akhtar M, Beckwith BJ et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133

    Article  CAS  PubMed  Google Scholar 

  4. Veltri A, Garetto I, Tosetti I et al (2011) Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 21:393–401

    Article  PubMed  Google Scholar 

  5. Leveridge MJ, Finelli A, Kachura JR et al (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60:578–584

    Article  PubMed  Google Scholar 

  6. Macari M, Bosniak MA (1999) Delayed CT to evaluate renal masses incidentally discovered at contrast-enhanced CT: demonstration of vascularity with deenhancement. Radiology 213:674–680

    Article  CAS  PubMed  Google Scholar 

  7. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol Off J Am Soc Clin Oncol 21:3955–3964

    Article  CAS  Google Scholar 

  8. Sun MR, Ngo L, Genega EM et al (2009) Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes—correlation with pathologic findings. Radiology 250:793–802

    Article  PubMed  Google Scholar 

  9. Kim JH, Bae JH, Lee KW, Kim ME, Park SJ, Park JY (2012) Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging. Urology 80:872–876

    Article  PubMed  Google Scholar 

  10. Vargas HA, Chaim J, Lefkowitz RA et al (2012) Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology 264:779–788

    Article  PubMed  Google Scholar 

  11. Wang H, Cheng L, Zhang X et al (2010) Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 257:135–143

    Article  PubMed  Google Scholar 

  12. Taouli B, Thakur RK, Mannelli L et al (2009) Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 251:398–407

    Article  PubMed  Google Scholar 

  13. Yuen JS, Thng CH, Tan PH et al (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171:1482–1486

    Article  CAS  PubMed  Google Scholar 

  14. Haddadin IS, McIntosh A, Meisamy S et al (2009) Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 22:65–76

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Katz-Brull R, Rofsky NM, Morrin MM et al (2005) Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 288:F637–F641

    Article  CAS  PubMed  Google Scholar 

  16. Sullentrop F, Hahn J, Moka D (2012) In vitro and in vivo (1)H-MR spectroscopic examination of the renal cell carcinoma. Int J Biomed Sci (IJBS) 8:94–108

    CAS  Google Scholar 

  17. Kim DY, Kim KB, Kim OD, Kim JK (1998) Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney. J Korean Med Sci 13:49–53

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Righi V, Mucci A, Schenetti L et al (2007) Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res 27:3195–3204

    CAS  PubMed  Google Scholar 

  19. Hammer S, de Vries AP, de Heer P et al (2013) Metabolic imaging of human kidney triglyceride content: reproducibility of proton magnetic resonance spectroscopy. PLoS One 8:e62209

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Naressi A, Couturier C, Devos JM et al (2001) Java-based graphical user interface for the MRUI quantitation package. Magma 12:141–152

    Article  CAS  PubMed  Google Scholar 

  21. Baltzer PA, Dietzel M (2013) Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T—systematic review and meta-analysis. Radiology 267:735–746

    Article  PubMed  Google Scholar 

  22. Mancini V, Battaglia M, Ditonno P et al (2008) Current insights in renal cell cancer pathology. Urol Oncol 26:225–238

    Article  CAS  PubMed  Google Scholar 

  23. Jorns J, Thiel DD, Lohse CM et al (2012) Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int 110(7):956–960

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest. There are no financial relationships related to this manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Sabina Sevcenco, Franklin E. Kuehhas, Harun Fajkovic & Sharokh F. Shariat

  2. Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Martin Krssak, Domagoj Javor, Lothar Ponhold & Pascal A. Baltzer

  3. Department of Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

    Andrea Haitel

Authors
  1. Sabina Sevcenco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Krssak
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domagoj Javor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lothar Ponhold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Franklin E. Kuehhas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Harun Fajkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Haitel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sharokh F. Shariat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pascal A. Baltzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pascal A. Baltzer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sevcenco, S., Krssak, M., Javor, D. et al. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. World J Urol 33, 17–23 (2015). https://doi.org/10.1007/s00345-014-1272-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1272-y

Keywords

Search

Navigation